
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: Feb. 24, 2025
nuclear-associated antigen Ki67 (Ki67) emerges as a clinically practical biomarker for proliferation assessment among many cancer types. However, the definite prognostic value of against specific type has remained vague. This study aims to perform comprehensive pan-cancer analysis prognosis across various explored expression, value, and tumor-infiltrating immune MKI67 in TCGA database by pan-cancer, then performed immunohistochemical, correlation using 10028 patients top 10 China we collected. The between expression survival outcome, clinical features, MSI, TMB, cells database, xCell, TIMER algorithms. was significantly upregulated varied types verified datasets. We found associated with poor LUADLUSC, LIHC, BRCA patients, but good COADREAD READ via Kaplan-Meier These results our validation were generally consistent except BRCA, READ. Meanwhile, upregulation elevates degree infiltration several cell subtypes, such functional T cells, CD4+ CD8+ well as, related Cell cycle, Oocyte meiosis, p53 other pathways. Our may supply useful guidance on applicability observed contribute promise realistic setting improve outcomes patients.
Language: Английский